Pharmaceutical Technology

JUNE 24, 2022

invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. for each share in cash.

Biopharma 64

Biopharma Pharma Pharmacology Healthcare 64

pharmaphorum

AUGUST 11, 2022

The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting.

Pharmacology 57

Pharmacology Biopharma Pharma 57

MedCity News

JUNE 16, 2023

Numerous clinical, regulatory and financial factors are behind this digital shift in pharma. And in the first quarter of this year, the largest Series A ever in digital health ($203M) went into a company accelerating clinical trials and drug development.

Pharma 96

Pharma Food and Drug Administration Recruitment Pharmacology 96

Pharmaceutical Technology

MAY 15, 2023

As molecular targeting peptides, anti-cancer peptides penetrate the plasma membrane, nuclear membrane, and mitochondrial membrane of cancer cells, exerting pharmacological activity through various mechanisms (such as inhibiting DNA synthesis and cell division), thus causing apoptosis of cancer cells.

Leads 52

Leads Biopharma Pharmaceutical Pharma 52

Pharmaceutical Technology

MAY 24, 2023

Several tetrapeptides are pharmacologically active, showing affinity and specificity for multiple receptors in protein-protein signalling. Whilst Abliva and Ambrx Biopharma stand in second and third positions, respectively. Merck 42 Unlock company profile C. Menarini Industrie Farmaceutiche Riunite.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Pharmacology 52

pharmaphorum

DECEMBER 20, 2022

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. Although, so far efforts to bring a therapy to market have failed.

Pharmacology 52

Pharmacology Pharma Marketing Biopharma 52

Clarivate

DECEMBER 14, 2023

Here are a few trends in life sciences and healthcare our analysts are keeping an eye on – and what they expect to see in 2024: Move over, oncology – metabolic drugs are the new hotness: The successful launches of Novo Nordisk’s Wegovy® and Eli Lilly’s Mounjaro® represent a revolutionary pharmacological breakthrough of rare proportions.

Pharma 111

Pharma Pharmacology Government Healthcare 111